RT Journal Article
SR Electronic
T1 Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.10.21264812
DO 10.1101/2021.10.10.21264812
A1 Uschner, Diane
A1 Bott, Matthew
A1 Santacatterina, Michele
A1 Gunaratne, Mihili
A1 Fette, Lida M.
A1 Burke, Brian
A1 Strylewicz, Greg
A1 Edelstein, Sharon L.
A1 Lagarde, William H
A1 Miller, Kristen
A1 Weintraub, William S.
A1 Keating, Joseph
A1 Schieffelin, John
A1 Yukich, Joshua
A1 Tapp, Hazel
A1 Ahmed, Amina
A1 Berry, Andrea A.
A1 Munawar, Iqra
A1 Seals, Austin Lyles
A1 Williamson, John
A1 Herrington, David
A1 Sanders, John W.
A1 Runyon, Michael
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/10/13/2021.10.10.21264812.abstract
AB Importance Real-world data are needed to assess incidence and factors associated with breakthrough SARS-CoV-2 infections following vaccination.Objective Estimate incidence of breakthrough infections and assess associations with risk factors using self-reported data from a large NC population sample.Design Prospective observational cohort study utilizing daily online survey data to capture information about COVID-19 symptoms, testing, and vaccination status.Setting Six health care systems in North Carolina with data collected between January 15, 2021 and September 24, 2021.Participants Adult study participants who reported full vaccination with a COVID-19 mRNA or J&J non-replicating viral vector vaccine (n =16,020).Exposures Potential community exposure to SARS-CoV-2.Main Outcome and Measures Self-reported breakthrough infection.Results SARS-CoV-2 infection after vaccination was self-reported in 1.9% of participants, with an incidence rate of 7.3 per 100,000 person-years. Younger age (45-64 vs. 18-44: HR (95% CI) = 0.65 (0.51 - 0.82); 65+ vs. 18-44: HR (95% CI) = 0.59 (0.39 - 0.90)), and vaccination with J&J Ad26.COV2.S were associated with a higher risk of breakthrough infection compared to vaccination with Pfizer BNT162b2 (Ad26.COV2.S vs. BNT162b2: HR (95% CI) = 2.23 (1.40 - 3.56)), while participants vaccinated with mRNA-1273 (mRNA-1273 vs. BNT162b2: HR (95% CI) = 0.69 (0.50 – 0.96) and those residing in urban counties experienced a lower rate of SARS-CoV-2 breakthrough infection compared with those from suburban (HR (95% CI) = 1.39 (1.01 – 1.90) or rural (HR (95% CI) = 1.57 (1.16 – 2.11) counties. There was no significant association between breakthrough infection and participant sex, race, healthcare worker status, prior COVID-19 infection, routine mask use, or overall vaccination rate in the county of residence.Conclusions and Relevance This NC community-based observational study showed that the proportion of the cohort who self-report breakthrough SARS-CoV-2 infections was 7.3 events per 100,000 person-years. Younger adults, those vaccinated with J&J Ad26.COV2.S, and those residing in suburban or rural counties were at higher risk of breakthrough infections and should be targeted for additional risk mitigation strategies to decrease community transmission.Trial Registration The COVID-19 Community Research Partnership is listed in clinicaltrials.gov (NCT04342884).Question What are the characteristics of those with breakthrough infections after SARS-CoV-2 vaccination in North CarolinaãFindings In this NC-based observational study of 16,020 participants, 1.9% self-reported a positive SARS-CoV-2 viral test at least 2 weeks following full vaccination, reflecting an event rate of 7.3 infections per 100,000 person years. Rates were higher among younger participants, participants from more rural areas in North Carolina, and those vaccinated with J&J Ad26.COV2.S.Meaning Our results show a relatively low rate of COVID-19 infection following full vaccination. Younger adults and those vaccinated with J&J Ad26.COV2.S should be targeted for additional risk mitigation strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the CARES Act of the U.S. Department of Health and Human Services (HHS) [Contract # NC DHHS GTS #49927]Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the Wake Forest School of Medicine gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.